Biotechnology
Build Your Comparison
Side-by-side financial analysisStock Comparison
ADAG vs XNCR
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
ADAG vs XNCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $210M | $904M |
| Revenue (TTM) | $103K | $93M |
| Net Income (TTM) | $-55M | $-172M |
| Gross Margin | -10.9% | 94.4% |
| Operating Margin | -589.5% | -144.7% |
| Total Debt | $18M | $188M |
| Cash & Equiv. | $85M | $54M |
ADAG vs XNCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 21 | Jun 26 | Return |
|---|---|---|---|
| Adagene Inc. (ADAG) | 100 | 14.6 | -85.4% |
| Xencor, Inc. (XNCR) | 100 | 25.0 | -75.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ADAG vs XNCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ADAG is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.73
- Lower volatility, beta 0.73, Low D/E 36.6%, current ratio 2.30x
- Beta 0.73, current ratio 2.30x
XNCR carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 13.7%, EPS growth 65.4%, 3Y rev CAGR -8.6%
- -12.6% 10Y total return vs ADAG's -88.1%
- 13.7% revenue growth vs ADAG's -99.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.7% revenue growth vs ADAG's -99.4% | |
| Quality / Margins | -185.7% margin vs ADAG's -537.2% | |
| Stability / Safety | Beta 0.73 vs XNCR's 1.72 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +82.1% vs XNCR's +30.8% | |
| Efficiency (ROA) | -20.5% ROA vs ADAG's -83.3% |
ADAG vs XNCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ADAG vs XNCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
XNCR leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
XNCR is the larger business by revenue, generating $93M annually — 899.6x ADAG's $103,204. XNCR is the more profitable business, keeping -185.7% of every revenue dollar as net income compared to ADAG's -537.2%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $103,204 | $93M |
| EBITDAEarnings before interest/tax | -$59M | -$127M |
| Net IncomeAfter-tax profit | -$55M | -$172M |
| Free Cash FlowCash after capex | -$48M | -$189M |
| Gross MarginGross profit ÷ Revenue | -10.9% | +94.4% |
| Operating MarginEBIT ÷ Revenue | -589.5% | -144.7% |
| Net MarginNet income ÷ Revenue | -537.2% | -185.7% |
| FCF MarginFCF ÷ Revenue | -461.1% | -2.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -50.0% | -159.1% |
Valuation Metrics
XNCR leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $210M | $904M |
| Enterprise ValueMkt cap + debt − cash | $144M | $1.0B |
| Trailing P/EPrice ÷ TTM EPS | -3.76x | -9.94x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 2037.00x | 7.20x |
| Price / BookPrice ÷ Book value/share | 2.55x | 1.44x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
XNCR leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
XNCR delivers a -28.8% return on equity — every $100 of shareholder capital generates $-29 in annual profit, vs $-146 for ADAG. XNCR carries lower financial leverage with a 0.30x debt-to-equity ratio, signaling a more conservative balance sheet compared to ADAG's 0.37x. On the Piotroski fundamental quality scale (0–9), XNCR scores 3/9 vs ADAG's 1/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -146.2% | -28.8% |
| ROA (TTM)Return on assets | -83.3% | -20.5% |
| ROICReturn on invested capital | — | -16.3% |
| ROCEReturn on capital employed | -53.1% | -21.6% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | 0.37x | 0.30x |
| Net DebtTotal debt minus cash | -$67M | $134M |
| Cash & Equiv.Liquid assets | $85M | $54M |
| Total DebtShort + long-term debt | $18M | $188M |
| Interest CoverageEBIT ÷ Interest expense | -46.92x | -0.98x |
Total Returns (Dividends Reinvested)
ADAG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XNCR five years ago would be worth $3,303 today (with dividends reinvested), compared to $2,627 for ADAG. Over the past 12 months, ADAG leads with a +82.1% total return vs XNCR's +30.8%. The 3-year compound annual growth rate (CAGR) favors ADAG at 42.3% vs XNCR's -23.1% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +94.0% | -17.4% |
| 1-Year ReturnPast 12 months | +82.1% | +30.8% |
| 3-Year ReturnCumulative with dividends | +187.9% | -54.5% |
| 5-Year ReturnCumulative with dividends | -73.7% | -67.0% |
| 10-Year ReturnCumulative with dividends | -88.1% | -12.6% |
| CAGR (3Y)Annualised 3-year return | +42.3% | -23.1% |
Risk & Volatility
ADAG leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ADAG is the less volatile stock with a 0.73 beta — it tends to amplify market swings less than XNCR's 1.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ADAG currently trades 75.2% from its 52-week high vs XNCR's 66.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.73x | 1.72x |
| 52-Week HighHighest price in past year | $4.75 | $18.69 |
| 52-Week LowLowest price in past year | $1.30 | $6.92 |
| % of 52W HighCurrent price vs 52-week peak | +75.2% | +66.0% |
| RSI (14)Momentum oscillator 0–100 | 49.9 | 52.9 |
| Avg Volume (50D)Average daily shares traded | 214K | 715K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ADAG as "Buy" and XNCR as "Buy". Consensus price targets imply 110.9% upside for XNCR (target: $26) vs 40.1% for ADAG (target: $5).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $5.00 | $26.00 |
| # AnalystsCovering analysts | 5 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
XNCR leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). ADAG leads in 2 (Total Returns, Risk & Volatility).
ADAG vs XNCR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ADAG or XNCR a better buy right now?
For growth investors, Xencor, Inc.
(XNCR) is the stronger pick with 13. 7% revenue growth year-over-year, versus -99. 4% for Adagene Inc. (ADAG). Analysts rate Adagene Inc. (ADAG) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ADAG or XNCR?
Over the past 5 years, Xencor, Inc.
(XNCR) delivered a total return of -67. 0%, compared to -73. 7% for Adagene Inc. (ADAG). Over 10 years, the gap is even starker: XNCR returned -12. 6% versus ADAG's -88. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ADAG or XNCR?
By beta (market sensitivity over 5 years), Adagene Inc.
(ADAG) is the lower-risk stock at 0. 73β versus Xencor, Inc. 's 1. 72β — meaning XNCR is approximately 136% more volatile than ADAG relative to the S&P 500. On balance sheet safety, Xencor, Inc. (XNCR) carries a lower debt/equity ratio of 30% versus 37% for Adagene Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ADAG or XNCR?
By revenue growth (latest reported year), Xencor, Inc.
(XNCR) is pulling ahead at 13. 7% versus -99. 4% for Adagene Inc. (ADAG). On earnings-per-share growth, the picture is similar: Xencor, Inc. grew EPS 65. 4% year-over-year, compared to -75. 9% for Adagene Inc.. Over a 3-year CAGR, XNCR leads at -8. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ADAG or XNCR?
Xencor, Inc.
(XNCR) is the more profitable company, earning -73. 2% net margin versus -323. 9% for Adagene Inc. — meaning it keeps -73. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XNCR leads at -141. 4% versus -348. 4% for ADAG. At the gross margin level — before operating expenses — XNCR leads at 91. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ADAG or XNCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ADAG or XNCR better for a retirement portfolio?
For long-horizon retirement investors, Adagene Inc.
(ADAG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73)). Xencor, Inc. (XNCR) carries a higher beta of 1. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ADAG: -88. 1%, XNCR: -12. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ADAG and XNCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.